A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Sponsor:

Alliance for Clinical Trials in Oncology

Sponsor Study ID:

A051902

CTO #:

103406

NCT Number:

NCT04803201

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Non-Hodgkin's Lymphoma

Study Objectives:

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)